- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01978301
Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars
May 12, 2017 updated by: GlaxoSmithKline
A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials
This is a 3-arm randomised clinical enabling study, with no investigational product.
Keloid patients who are scheduled for surgical excision of one or more keloid scars (up to nine) will be recruited to the study.
The aim is to investigate how collagen synthesis within keloid scars is affected by the current approved steroid treatment for keloids, triamcinolone acetonide (TAC).
The primary endpoint will be fractional collagen synthesis in keloids which have received intra-lesional injections of TAC, placebo or no treatment prior to their removal.
Fractional collagen synthesis will be determined using an established isotope/mass spectrometric technique which measures levels of deuterium incorporation into collagen following administration of heavy water to the subject.
In addition; keloid tissue samples will be evaluated post surgery to identify further biomarkers of extracellular matrix synthesis and degradation for application in future clinical studies.
Subjects will complete a screening visit and will then be randomised to receive three intra-lesional injections of TAC or placebo, or no treatment, at an interval of 2-3 weeks.
Subjects will be randomised to different treatment sequences depending on the number of keloids they have scheduled for surgery, in such a way that subjects with multiple keloids will receive different arms of study treatment in their different keloids.
Planned surgery for removal of their keloid(s) will be performed at week 6-8.
All subjects will receive daily heavy water (Deuterium oxide) administration (twice daily or thrice daily as directed), with the first dose being taken at the Week 2 clinic visit and the final dose being taken on the day prior to surgery.
A follow-up visit will be conducted at 1-4 weeks post-surgery.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, E1 2AT
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects have at least one keloid scar scheduled for removal as part of their normal course of treatment
- Males or females aged between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of: Child-bearing potential with negative pregnancy test as determined by urine human chorionic gonadotropin (hCG) test at screening, AND; agrees not to become pregnant during the course of the study and for at least 1 month after completion of heavy water consumption; OR is of non child-bearing potential
- Male subjects must agree not to father a child during the study and for at least 1 month after completion of heavy water consumption.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
Exclusion Criteria:
- Keloids to be randomised must not have received steroid treatment for at least two months prior to screening.
- Evidence of other skin conditions or scarring in the region of keloid scaring (including but not limited to: hypertrophic scars, eczema, psoriasis, etc.) unless the Investigator, in consultation with the GSK medical monitor, agree that the condition is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of regular alcohol consumption that could preclude safe completion of the study.
- History of sensitivity to corticosteroids or history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
- Subjects currently receiving oral corticosteroids.
- Subjects with a recent history of tuberculosis (TB) (within last three years).
- Evidence or recent history (past two weeks) of any infection (viral, bacterial, fungal, protozoan, or helminthic).
- History of recurrent fungal infection.
- Lactating females.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Triamcinolone acetonide
Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
|
Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
|
PLACEBO_COMPARATOR: Placebo
Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
|
Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
|
NO_INTERVENTION: No treatment
Keloid(s) assigned 'No Treatment' will not receive any treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fractional synthesis of collagen in keloid scars
Time Frame: Week 6-8
|
Post surgical excision of keloids, tissue samples will be obtained by snap frozen biopsies.
Fractional synthesis of collagen (that is, the fraction of the collagen that is newly synthesised during the labelling period) will be determined using mass spectrometry which measures the levels of deuterium incorporation into hydroxyproline or alanine in the collagen from the excised tissue samples, following administration of heavy water (Deuterium oxide) to the subject
|
Week 6-8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Keloid scar volume before first dose and immediately prior to surgery
Time Frame: Day 1 and Week 6-8
|
For each keloid under evaluation, the keloid volume will be measured using three-dimensional (3D) photography
|
Day 1 and Week 6-8
|
Keloid scar surface area before first dose and immediately prior to surgery
Time Frame: Day 1 and Week 6-8
|
For each keloid under evaluation, the keloid surface area will be measured using 3D photography
|
Day 1 and Week 6-8
|
Keloid scar length and height before first dose and immediately prior to surgery
Time Frame: Day 1 and Week 6-8
|
For each keloid under evaluation, the keloid length and height will be measured using 3D photography
|
Day 1 and Week 6-8
|
Keloid scar vascularity before first dose and immediately prior to surgery
Time Frame: Day 1 and Week 6-8
|
For each keloid under evaluation, the keloid vascularity will be measured by laser Doppler
|
Day 1 and Week 6-8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 15, 2014
Primary Completion (ACTUAL)
February 5, 2015
Study Completion (ACTUAL)
February 5, 2015
Study Registration Dates
First Submitted
October 31, 2013
First Submitted That Met QC Criteria
October 31, 2013
First Posted (ESTIMATE)
November 7, 2013
Study Record Updates
Last Update Posted (ACTUAL)
May 15, 2017
Last Update Submitted That Met QC Criteria
May 12, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Connective Tissue Diseases
- Cicatrix
- Collagen Diseases
- Fibrosis
- Keloid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- 117287
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrosis
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
San Gerardo HospitalCompletedIdiopathic Pulmonary Fibrosis | Cardiac Fibrosis | Arterial FibrosisItaly
-
Assistance Publique - Hôpitaux de ParisRecruitingIdiopathic Retroperitoneal FibrosisFrance
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
University of ParmaUnknownIdiopathic Retroperitoneal Fibrosis | Perianeurysmal Retroperitoneal Fibrosis | Chronic PeriaortitisItaly
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University Hospital, GrenobleNot yet recruiting
Clinical Trials on Triamcinolone acetonide
-
Weill Medical College of Cornell UniversityCompletedNail Diseases | Nail PsoriasisUnited States
-
Clearside Biomedical, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis | Noninfectious UveitisUnited States
-
Novartis PharmaceuticalsCompletedAcute Gouty Arthritis FlaresUnited States, Estonia, Lithuania, Germany, Russian Federation, Canada, Australia, Latvia, Ukraine
-
University of North Carolina, Chapel HillCompletedHidradenitis SuppurativaUnited States
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); AllerganCompletedDiabetic Macular EdemaUnited States
-
Shahid Beheshti University of Medical SciencesCompletedDiabetic Macular EdemaIran, Islamic Republic of
-
Patel, Rita Vikram, M.D.Ranbaxy Inc.CompletedAcute Steroid Responsive Dermatoses | Chronic Steroid Responsive DermatosesUnited States
-
SurModics, Inc.CompletedDiabetic Macular EdemaUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknown
-
Edward Hines Jr. VA HospitalUnknown